Omalizumab (Xolair)

Indications

Allergic Bronchopulmonary Candidiasis (see Candida, [[Candida]])

  • xxx

Asthma (see Asthma, [[Asthma]])

  • Trial of Omalizumab for Asthma in Inner-City Children (NEJM, 2011) [MEDLINE]: omalizumab added to standard asthma therapy in inner-city children/adolescents/young adults
    • Omalizumab Decreased the Number of Days with Asthma Symptoms
    • Omalizumab Decreased Asthma Exacerbations: nearly eliminating seasonal peaks in exacerbations
    • Omalizumab Decreased the Need for Other Medications to Control Asthma
  • Cochrane Database Systematic Review Examining Omalizumab in Adults/Children with Asthma (2014) [MEDLINE]
    • As Adjunct to Inhaled Corticosteroids (and During Corticosteroid Tapering), Omalizumab Decreased Asthma Exacerbations/Hospitalizations
    • Omalizumab was Effective in Allowing Corticosteroid Taper/Withdrwal
    • Unclear Whether There is a Threshold Level of Serum IgE Which Predicts Optimal Efficacy of Omalizumab

Pharmacology

  • Anti-IgE

Metabolism

  • xxx

Administration

  • xxxx: xxx

Dose Adjustment

  • Hepatic
  • Renal

Adverse Effects

xxx

  • xxx

Other Adverse Effects

  • Injection Site Reaction

References

  • Randomized trial of omalizumab (Anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-1015 [MEDLINE]
  • Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy. Ann Intern Med 2011;154:573-582 [MEDLINE]
  • Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014 Jan 13;1:CD003559. doi: 10.1002/14651858.CD003559.pub4 [MEDLINE]